Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jval.2013.08.1507PMID 26633622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review.

  2015cited by this paper
• Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.

  2015cited by this paper
• Italian population-based values of EQ-5D health states.

  2013cited by this paper
• Pharmacoeconomic Issues in Psoriatic Arthritis

  2012cited by this paper
• Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.

  2012cited by this paper
• The rationale of pharmacoeconomic analysis in rheumatologic indications.

  2012cited by this paper
• Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.

  2011cited by this paper
• Challenges in Economic Evaluation of Psoriatic Arthritis

  2010cited by this paper
• Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

  2009cited by this paper
• Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

  2008cited by this paper
• The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy

  2008cited by this paper
• Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

  2006cited by this paper
• Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

  2006cited by this paper
• The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

  2006cited by this paper
• Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

  2004cited by this paper
• Assessment of patients with psoriatic arthritis: a review of currently available measures.

  2004cited by this paper
• International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

  2003cited by this paper
• Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis

  2003cited by this paper
• TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

  2003cited by this paper
• Comparison of disability and quality of life in rheumatoid and psoriatic arthritis.

  2001cited by this paper
• A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States

  2001cited by this paper
• EuroQol: the current state of play.

  1996cited by this paper
• A Review of the Progress Towards Developing Health-Related Quality-of-Life Instruments for International Clinical Studies and Outcomes Research

  1996cited by this paper
• A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

  1994cited by this paper
• A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

  1994cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

  1984cited by this paper
• Measurement of patient outcome in arthritis.

  1980cited by this paper
• Severe psoriasis--oral therapy with a new retinoid.

  1978cited by this paper

• Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry

  2024cites this paper
• A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy

  2023cites this paper
• Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

  2022influential citation
• Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study

  2021influential citation
• Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis

  2019cites this paper
• Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population

  2019cites this paper
• Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review

  2018influential citation
• Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases

  2018cites this paper
• Economic evaluations in the context of treatment recommendations in spondyloarthritis : analyses from the DESIR cohort

  2017influential citation
• Feasibility , acceptability and construct validity of EQ-5 D in systemic sclerosis

  2017cites this paper
• Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors

  2017cites this paper
• Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis

  2017cites this paper
• Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis.

  2016cites this paper
• A national survey on the management of psoriatic arthritis using the Delphi method.

  2016cites this paper
• The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review.

  2016cites this paper
• Burden of disease in psoriasis and psoriatic arthritis. Occurrence, healthcare use, costs and health outcomes.

  2016cites this paper
• The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review.

  2016cites this paper